论文部分内容阅读
目的 明确趋化因子CCL27在继发性中耳胆脂瘤中的病理学表达，探讨可能的临床意义。方法 应用免疫组织化学SP法检测CCL27在继发性中耳胆脂瘤（n=30）及正常耳后皮肤组织(n=30)的表达情况，并分析该趋化因子与胆脂瘤病理学之间的联系。结果 继发性胆脂瘤、耳后皮肤组织中CCL27的阳性率分别为6.7％和33.3％，差异有统计学意义(P=0.021)。结论 继发性胆脂瘤组织中CCL27的低表达可能与胆脂瘤的增殖过于活跃有关，CCL27可能在继发性中耳胆脂瘤发病过程中扮演重要角色。
Objective To clarify the pathological expression of chemokine CCL27 in secondary middle ear cholesteatoma and to explore the possible clinical significance. Methods Immunohistochemical SP method was used to detect the expression of CCL27 in secondary middle ear cholesteatoma (n = 30) and normal posterior ear skin (n = 30), and to analyze the relationship between the chemokine and cholesteatoma pathology the relationship between. Results The positive rates of CCL27 in secondary cholesteatoma and auricular skin were 6.7% and 33.3%, respectively, with significant difference (P = 0.021). Conclusions The low expression of CCL27 in secondary cholesteatoma may be related to the hyperproliferation of cholesteatoma. CCL27 may play an important role in the pathogenesis of secondary cholesteatoma.